Teva

Bethel Free Clinic, a nonprofit medical establishment, provides complimentary healthcare services to those without insurance. It offers services including primary care, acute care, laboratory testing, health education, help with prescriptions, referrals to specialists, and preventive measures such as vaccinations and STD testing.

Anda, Inc. operates as a wholesale distributor of pharmaceutical products in the United States. It distributes generic, branded, and specialty pharmaceuticals, as well as CII products, vaccines, injectables, medical/surgical supplies, and OTCs/vitamins to independent pharmacies, hospitals, nursing homes, mail order pharmacies, pharmacy chains, and physicians’ offices. The company markets products through phone, fax, and online orders. Anda, Inc. was formerly known as Anda Generics, Inc. and changed its name to Anda, Inc. in October 1999. The company was founded in 1992 and is based in Weston, Florida. Anda, Inc. operates as a subsidiary of Watson Pharmaceuticals, Inc.

Wave Life Sciences Ltd. is a clinical-stage genetic medicine company focused on developing innovative RNA-based therapies. Utilizing its proprietary PRISM platform, the company designs, optimizes, and produces stereopure oligonucleotides aimed at addressing genetic defects. By targeting ribonucleic acid (RNA), Wave aims to either diminish the production of harmful proteins or convert dysfunctional proteins into functional ones. The company's primary focus is on neurology, particularly disorders affecting the central and neuromuscular systems. Wave Life Sciences has established research and collaboration agreements with major pharmaceutical companies, including Pfizer and Takeda, to further advance its therapeutic programs. Founded in 2012 and headquartered in Singapore, Wave Life Sciences is dedicated to delivering transformative treatments for patients with genetically defined diseases.

Rimsa, a leading pharmaceutical manufacturing and distribution company in Mexico

CareTRx by Gecko Health is a product and services to improve poor medication adherence for asthma and COPD medication. The company offers a unique solution based on direct monitoring, games and social tools that motivate patients, engage care-givers, and inform clinicians. GeckoCap simplifies adherence to help families and lower costs.

Microchips Biotech, Inc. is dedicated to improving the lives of patients by revolutionizing drug delivery. Our proprietary microchip-based implant can store and release precise doses of drugs over months and years. The implant, which is placed under the skin by a trained physician during a simple office procedure using local anesthesia, can be wirelessly activated or deactivated by a physician or patient, without requiring removal. In addition, physicians can wirelessly modify the frequency or dose of the drug to meet the individual needs of each patient.

Auspex Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative medicines for orphan diseases. The company focuses on creating deuterated analogs of clinically validated drugs, aiming to improve existing therapies across various therapeutic areas. Its pipeline includes candidates targeting unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome. Additionally, Auspex seeks to address other orphan indications, as well as conditions related to respiratory disease and inflammation.

Ignyta, Inc. is a biotechnology company focused on discovering, developing, and commercializing targeted therapies for cancer treatment. Based in San Diego, California, Ignyta specializes in molecularly targeted therapies aimed at eradicating residual diseases and improving patient outcomes. The company's key products include entrectinib, a tyrosine kinase inhibitor that targets specific proteins associated with various cancers, and RXDX-105, which is designed to treat RET-driven solid tumors. Additionally, Ignyta emphasizes the integration of companion diagnostics to better match therapies with patients likely to benefit from them. Founded in 2011, the company operates as a subsidiary of Roche Holdings, Inc., underscoring its commitment to advancing precision medicine in oncology.

Labrys Biologics Inc. is a biotechnology company dedicated to developing treatments for chronic migraine. The company has secured worldwide rights to RN-307, an antibody initially developed by Pfizer Inc., specifically designed for the treatment of chronic migraine. Additionally, Labrys Biologics is advancing its lead candidate, LBR-101, which is an anti-CGRP monoclonal antibody aimed at preventing chronic and high-frequency migraines. Through these innovative therapies, Labrys Biologics aims to address the significant unmet medical needs of individuals suffering from chronic migraine conditions.

NuPathe Inc. is a specialty pharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two proprietary product candidates based on its LAD™, or Long-Acting Delivery, biodegradable implant technology that allows delivery of therapeutic levels of medication over a period of months with a single dose. NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes a leading FDA-approved dopamine agonist, ropinirole, and is being developed to provide up to two months of continuous delivery. NP202, for the long-term treatment of schizophrenia and bipolar disorder, is being developed to address the long-standing problem of patient noncompliance by providing three months of continuous delivery of risperidone, an atypical antipsychotic. NuPathe is actively seeking partnerships to maximize the commercial potential for its product candidates in the U.S. and territories throughout the world.

MicroDose Therapeutx is a specialty pharmaceutical company based in South Brunswick Township, New Jersey, focused on developing advanced drug delivery products. Its primary innovations include a novel electro-mechanical dry powder inhaler and PolyCap technologies, which aim to enhance the efficacy and convenience of pharmaceutical treatments. The company serves the pharmaceutical and biotechnology industries, providing innovative solutions that address the challenges of traditional drug delivery methods.

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

Cocrystal Discovery is a privately funded biotechnology company developing antiviral therapeutics for human diseases. Cocrystal has breakthrough technologies that enable the creation of first- and best-in-class antivirals. Their mission today is to discover and develop small molecule inhibitors of the viral replication complex.

CIMA LABS is Pharmaceutical and biotech companies partner with CIMA for its drug delivery technologies and proven commercialization success.

Barr Pharmaceuticals was a global specialty pharmaceutical company that operated in more than 30 countries worldwide.

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transdermal drug delivery technology. Their current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transdermal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1.

BioLineRx Ltd. is a clinical-stage biopharmaceutical development company based in Modi’in, Israel, specializing in oncology. The company’s pipeline includes two primary therapeutic candidates: BL-8040, a novel peptide designed for treating solid tumors, hematological malignancies, and facilitating stem cell mobilization, and AGI-134, an immuno-oncology agent targeted at solid tumors. Additionally, BioLineRx offers BL-5010, a proprietary pen-like applicator intended for the non-surgical removal of skin lesions. The company actively collaborates with prominent organizations such as MSD, MD Anderson Cancer Center, and Genentech to explore innovative treatment combinations and advance its clinical studies. Established in 2003, BioLineRx focuses on addressing unmet medical needs in the pharmaceutical sector.

Proneuron Biotechnologies develops spinal cord injury treatments, researches cures for paralysis, and neurological therapies.

Copley Pharmaceutical is a generic pharmaceutical company that manufactured products for both over-the-counter and prescription sales.